We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan Urges FDA Not to Approve Advair Generics Based on Multi-Batch Studies
Mylan Urges FDA Not to Approve Advair Generics Based on Multi-Batch Studies
The FDA should not approve generics of Glaxo Smith Kline’s asthma drug Advair Diskus that depend on multiple-batch studies to show pharmacokinetic bioequivalence, according to Mylan.